Switch theme
Sign up to access all valuation multiples
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
1985
210
LTM Revenue $57.0M
LTM EBITDA $5.9M
$84.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Champions Oncology has a last 12-month revenue (LTM) of $57.0M and a last 12-month EBITDA of $5.9M.
In the most recent fiscal year, Champions Oncology achieved revenue of $50.2M and an EBITDA of -$5.1M.
Champions Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Champions Oncology valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $57.0M | XXX | $50.2M | XXX | XXX | XXX |
| Gross Profit | $26.7M | XXX | $20.8M | XXX | XXX | XXX |
| Gross Margin | 47% | XXX | 41% | XXX | XXX | XXX |
| EBITDA | $5.9M | XXX | -$5.1M | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | -10% | XXX | XXX | XXX |
| EBIT | $3.2M | XXX | -$6.9M | XXX | XXX | XXX |
| EBIT Margin | 6% | XXX | -14% | XXX | XXX | XXX |
| Net Profit | n/a | XXX | -$7.3M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | -15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Champions Oncology's stock price is $6.
Champions Oncology has current market cap of $81.2M, and EV of $84.4M.
See Champions Oncology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $84.4M | $81.2M | XXX | XXX | XXX | XXX | $0.29 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Champions Oncology has market cap of $81.2M and EV of $84.4M.
Champions Oncology's trades at 1.5x EV/Revenue multiple, and 37.0x EV/EBITDA.
Equity research analysts estimate Champions Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Champions Oncology's P/E ratio is not available.
See valuation multiples for Champions Oncology and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $81.2M | XXX | $81.2M | XXX | XXX | XXX |
| EV (current) | $84.4M | XXX | $84.4M | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | 14.4x | XXX | 37.0x | XXX | XXX | XXX |
| EV/EBIT | 26.3x | XXX | -934.3x | XXX | XXX | XXX |
| EV/Gross Profit | 3.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -12.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -19.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialChampions Oncology's last 12 month revenue growth is 7%
Champions Oncology's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Champions Oncology's rule of 40 is -1% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Champions Oncology's rule of X is 28% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Champions Oncology and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Growth | -17% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1% | XXX | 11% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 28% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 55% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Champions Oncology acquired XXX companies to date.
Last acquisition by Champions Oncology was XXXXXXXX, XXXXX XXXXX XXXXXX . Champions Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Champions Oncology founded? | Champions Oncology was founded in 1985. |
| Where is Champions Oncology headquartered? | Champions Oncology is headquartered in United States of America. |
| How many employees does Champions Oncology have? | As of today, Champions Oncology has 210 employees. |
| Who is the CEO of Champions Oncology? | Champions Oncology's CEO is Dr. Ronnie Morris, M.D.. |
| Is Champions Oncology publicy listed? | Yes, Champions Oncology is a public company listed on NAS. |
| What is the stock symbol of Champions Oncology? | Champions Oncology trades under CSBR ticker. |
| When did Champions Oncology go public? | Champions Oncology went public in 2007. |
| Who are competitors of Champions Oncology? | Similar companies to Champions Oncology include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Champions Oncology? | Champions Oncology's current market cap is $81.2M |
| What is the current revenue of Champions Oncology? | Champions Oncology's last 12 months revenue is $57.0M. |
| What is the current revenue growth of Champions Oncology? | Champions Oncology revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Champions Oncology? | Current revenue multiple of Champions Oncology is 1.5x. |
| Is Champions Oncology profitable? | Yes, Champions Oncology is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Champions Oncology? | Champions Oncology's last 12 months EBITDA is $5.9M. |
| What is Champions Oncology's EBITDA margin? | Champions Oncology's last 12 months EBITDA margin is 10%. |
| What is the current EV/EBITDA multiple of Champions Oncology? | Current EBITDA multiple of Champions Oncology is 14.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
